Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01209871 · ClinicalTrials.gov registry record · Phase 1
Vaccine Therapy in Treating Patients With Lymphoplasmacytic Lymphoma
A Phase 1 study of Lymphoplasmacytic Lymphoma, sponsored by M.D. Anderson Cancer Center.
- Active
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
- 1
- Study location
NCT01209871 is a Phase 1 study of Lymphoplasmacytic Lymphoma that is active but no longer recruiting, run by M.D. Anderson Cancer Center. The registered enrollment target is 9 participants, below the 108-participant average among 18 other Lymphoplasmacytic Lymphoma trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01209871, a Phase 1 study of Lymphoplasmacytic Lymphoma, is active but no longer recruiting, sponsored by M.D. Anderson Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase I trial studies the side effects and best dose of vaccine therapy in treating patients with lymphoplasmacytic lymphoma. Vaccines made from a person's cancer cells may help the body build an effective immune response to kill cancer cells.
Conditions Studied
Interventions
- OTHER Laboratory Biomarker Analysis
- BIOLOGICAL Autologous Lymphoma Immunoglobulin-derived scFv-chemokine DNA Vaccine
Study Locations (1)
Texas
- M D Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2015-02-26 |
| Est. Completion | 2026-02-20 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01209871
The ClinicalTrials.gov registry entry for NCT01209871 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 108-participant average among 18 other Lymphoplasmacytic Lymphoma trials with a reported enrollment target (92% lower). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Lymphoplasmacytic Lymphoma appearing as the primary indexed condition, and to 2 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT01209871 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT01209871 about?
NCT01209871 is a clinical study titled "Vaccine Therapy in Treating Patients With Lymphoplasmacytic Lymphoma". This phase I trial studies the side effects and best dose of vaccine therapy in treating patients with lymphoplasmacytic lymphoma. Vaccines made from a person's cancer cells may help the body build an effective immune response to kill cancer cells.
What is the current status of trial NCT01209871?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2015-02-26. Estimated completion is 2026-02-20.
What conditions does trial NCT01209871 study?
This clinical trial studies the following conditions: Lymphoplasmacytic Lymphoma.
What interventions are being tested in trial NCT01209871?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Autologous Lymphoma Immunoglobulin-derived scFv-chemokine DNA Vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT01209871?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01209871 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphoplasmacytic Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas
RECRUITING · Phase 1
-
Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma
RECRUITING · Phase 1
-
Copanlisib and Nivolumab in Treating Patients With Richter's Transformation or Transformed Indolent Non-Hodgkin Lymphoma
ACTIVE NOT RECRUITING · Phase 1
-
Oral Clofarabine for Relapsed/Refractory Non-Hodgkin Lymphoma
COMPLETED · Phase 1
-
Ph I Trial of NAM NK Cells and IL-2 for Adult Pts With MM and NHL
COMPLETED · Phase 1
-
Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.